# An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.

> **NCT01847222** · PHASE1 · TERMINATED · sponsor: **Prolong Pharmaceuticals** · enrollment: 2 (actual)

## Conditions studied

- Drug Safety

## Interventions

- **BIOLOGICAL:** SANGUINATE™
- **DRUG:** Normal Saline Solution

## Key facts

- **NCT ID:** NCT01847222
- **Lead sponsor:** Prolong Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05
- **Primary completion:** 2014-05
- **Final completion:** 2014-08
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Terminated due to completion of competing study.
- **Last updated:** 2015-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01847222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01847222, "An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01847222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*